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Identification of patients at risk of early
disease progression is the mainstay of
tailored management in chronic lympho-
cytic leukemia (CLL). Although applica-
tion of established biomarkers is limited
by intrinsic detection/readout complexi-
ties, abnormality of  and  serum-free
light chain ratio [sFLC (/)] was pro-
posed as a straightforward prognostica-
tor in CLL. By analyzing 449 therapy-
naive patients, we show that an abnormal
sFLC(/), along with CD38, ZAP-70, IGHV
mutations, cytogenetics and stage, inde-
pendently predicts treatment-free sur-
vival (TFS) but becomes prognostically
irrelevant if the cumulative amount of
clonal and nonclonal FLCs [sFLC(  )],
a variable associated with cytogenetic
risk, exceeds the threshold of 60.6 mg/
mL. Patients with sFLC(  ) above cut-
off displayed a poorer TFS outcome, irre-
spective of sFLC(/). Only ZAP-70,
cytogenetics, stage, and TFS remained
associated with sFLC(  ) in a multivar-
iate model. By assigning 1 point each for
these variables, the 3-year probability of
TFS was 94.8%, 84.5%, 61.6%, and 21.1%
for patients scoring 0, 1, 2, and 3  4,
respectively (P < .0001). These data, and
the demonstration that monoclonal and
polyclonal B cells concur to FLC synthe-
sis in tumor tissues, suggest that
sFLC(/) and sFLC(  ) mirror dis-
tinct biologic processes in CLL.
sFLC(  ) assessment represents a
sensitive and cost-effective tool for iden-
tifying CLL patients requiring early treat-
ment. (Blood. 2011;118(24):6353-6361)
Introduction
During physiologic lymphopoiesis, B cells and plasma cells mostly
produce an intact immunoglobulin (Ig), consisting of heavy chains
bound to a - or -light chain, together with an excess, approxi-
mately 40%, of unbound free light chains (FLCs).1 In plasma cell
malignancies, such as multiple myeloma (MM) and related disor-
ders, tumor cells usually secrete intact monoclonal Igs along with a
relative excess of clonally related FLCs, whereas, in rare cases,
only a clonal light chain without identifiable heavy chain is
produced.1 A straightforward nephelometric assay, the serum FLC
(sFLC) assay, has been developed that accurately measures the
amounts of free - and -light chains circulating in the serum as
monomers or dimers unbound to the Ig heavy chains.2 The assay
allows the detection of abnormalities in the physiologic ratios of
sFLCs [sFLC(/)], which can be used to reveal the presence of
clonal, - or -restricted tumor cell populations, and permits
quantization of sFLC absolute levels, which correlate with disease
activity and clinical outcome in patients with plasma cell malignan-
cies.3 In addition, sFLC elevations, with a conserved sFLC(/),
were shown to represent a tool to quantify ongoing polyclonal
B-cell activation/expansions, underlying the pathogenesis of vari-
ous chronic inflammatory and autoimmune conditions,4 as well as
to be an indirect way to measure progressive renal injury, which is
characterized by an impaired FLC catabolism.5
Although the relative ratio of intact Ig to FLC production in
B-cell malignancies other than MM has been relatively less
explored, early studies indicated that in chronic lymphocytic
leukemia (CLL) and some B-cell non-Hodgkin lymphomas, tumor
cells may display a significant imbalance in heavy and light chain
synthesis leading to the secretion of a large excess of FLCs
compared with heavy chains and intact Igs.6 Being a sensitive,
simple, and reproducible indicator of B-cell clonality and biologic
activity, the sFLC(/) test is particularly attractive as a putative
prognostic marker in CLL,7,8 a B-cell tumor whose clinical course
is highly heterogeneous across individual patients. Many patients
are asymptomatic and survive for decades without requiring
treatment, whereas others experience an aggressive form of disease
and may die of disease- or therapy-related complications shortly
after diagnosis. Within such a clinical framework, biologic predic-
tors of clinical progression would be of great value, at diagnosis, to
identify patients at risk of requiring early treatment and spare the
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toxic load of unnecessary therapy to those predicted to display an
indolent course.
A number of biomarkers, including ZAP-70, CD38, immuno-
globulin heavy chain variable gene (IGHV) mutation status, and
cytogenetic abnormalities, have been validated that rank the risk of
progressive disease and predict treatment requirement and survival
in the individual CLL patient.9 However, assessment methodolo-
gies, being complex and expensive, are not readily available in all
instances, mostly limiting application of these biomarkers to the
context of clinical trials and specific patient situations, also because
of reproducibility and standardization issues across laboratories.
Two previous reports have indicated that sFLC(/) abnormali-
ties are present in a significant proportion of CLL patients and
could independently identify those at risk of progressive disease.7,8
These retrospective studies, however, assessed small cohorts of
both therapy-naive and treated patients, leading to varied results as
to the prognostic value of sFLC(/), rather than absolute sFLC
levels, and the predictive power of sFLC abnormalities within the
framework of other CLL biomarkers.
By analyzing the largest cohort of therapy-naive CLL patients
so far reported, we wished to: (1) determine the independent
predictive value of sFLC abnormalities in the context of estab-
lished CLL biomarkers; (2) define the predictive hierarchy of these
markers; (3) dissect the prognostic relevance of sFLC(/) from
the predictive value of sFLC absolute levels; and (4) incorporate
sFLC-dependent variables into a novel prognostic system able to
predict treatment-free survival (TFS) in newly diagnosed patients.
Methods
Patients and study design
A total of 449 previously untreated CLL patients from a cooperative
network of Italian institutions were enrolled in a collaborative study. All
participants provided written informed consent in accordance with the
Declaration of Helsinki, and the study was approved by the relevant
institutional review boards. Inclusion criteria consisted of a diagnosis of
typical CLL based on National Cancer Institute, Working Group criteria10
and confirmed by flow cytometry.11-13 Availability of serum samples
obtained within 3 months from initial diagnosis in the absence of any
therapeutic intervention, including low-dose steroids and anti-inflammatory
treatments, was required at study entry. Table 1 summarizes the main
clinical and biologic data from this group. The median follow-up was
3.0 years, and 149 of 449 patients analyzed for clinical outcome had
received treatment by the end of the study. TFS was measured from
diagnosis to first-line treatment or last follow-up. Treatment was decided
uniformly in all participating centers based on documented progressive and
symptomatic disease according to National Cancer Institute, Working
Guidelines.10
CD38 and ZAP-70 determination, IGHV gene analysis, and
cytogenetics
All flow cytometric analyses reported in this study were performed on a
FACSCalibur flow cytometer (BD Biosciences). The expression of CD38
was analyzed by 3-color immunofluorescence,12,14 and the detection of
ZAP-70 was performed according to previously reported methods.12,14 The
cut-off of 30% positive cells was chosen to discriminate CD38 from
CD38 CLL.14 The cut-off levels of 20%15 or 30%16 were used to
distinguish ZAP-70 from ZAP-70 CLL, depending on anti–ZAP-70
antibody used and on each laboratory’s standardization of ZAP-70 flow
cytometric protocols.
IGHV gene usage and mutation status were determined using cDNA
according to previously published methods.17
Interphase FISHs were carried out for the detection of trisomy 12 and
chromosome deletion at 17p13.1, 11q22.3, and 13q14.3 loci. Dual-color
hybridizations using appropriate centromeric-specific probes and unique
sequence-specific probe for TP53 (LSI P53) and ATM (LSI ATM) loci, were
performed for the 17p13.1 and 11q23.3 deletions, respectively. For the
detection of 13q14.3 deletion, the locus-specific probe (LSI D13D25) was
cohybridized with the 13q34 telomeric probe as an internal control for
nullisomy. A chromosome 12-specific -satellite probe was used to identify
trisomy 12. All probes were purchased from Vysis, and FISH procedures
were performed following the manufacturer’s specifications. For each
hybridization, a minimum of 200 interphase nuclei were assessed.18
Patients were categorized into high (17p13.1 and 11q22.3 deletions),
intermediate (trisomy 12), and low (13q14.3 deletion and normal) risk
groups for subsequent analysis.
sFLC determination
Levels of sFLC were determined in all study samples using a particle
enhanced, high-specificity, homogeneous immuno-FLC assay (Freelite;
The Binding Site) performed on a Delta Nephelometer (Radim Diagnos-
tics). It consists of 2 separate measurements: the first to detect free- Ig
(normal range, 3.3-19.4 mg/L) and the other to detect free- Ig (normal
range, 5.7-26.3 mg/L) light chains. In addition to measuring absolute sFLC
protein levels, the test also allowed us to assess the presence or absence of
clonality based on the ratio of free- to - Ig concentrations (normal range,
0.26-1.65). We adjusted the reference ratios for normality of sFLC (0.37-3.1 mg/
L), as suggested by Hutchison et al,5 to reflect progressive changes in renal
function in patients with abnormal creatinine clearance. Finally, we
introduced a new variable (ie, the total amount of  and  light chains
[sFLC(  )]) determined by summing the free- plus free- chains.
In situ immunohistochemistry was performed on formalin-fixed, paraffin-
embedded lymph node and bone marrow samples relative to 4 CLL and
2 MM cases as previously reported.19 Briefly, tissue sections were
deparaffinized with xylene and rehydrated with water through a graded
alcohol series. Slides were microwave treated in citrate buffer, pH 6.0
(Dako North America) and, after Fc blocking with a specific blocking buffer
(Protein Block), incubated with the validated primary mouse monoclonal
Table 1. Clinical, biologic, and molecular features of CLL patients
included in the study
Parameter No. (%) of patients
Total patients 449
Age, y 449 (100)
Median 65
Range 33-89
Sex 449 (100)
Female 167 (37.2)
Male 282 (62.8)
Binet stage 449 (100)
A 331 (73.7)
B 67 (14.9)
C 51 (11.4)
ZAP-70 expression 401 (89.3)
Negative 261 (65.1)
Positive 140 (34.9)
CD38 expression 410 (91.3)
Negative 330 (80.5)
Positive 80 (19.5)
IGHV mutational status 379 (84.4)
Mutated 249 (65.7)
Unmutated 130 (34.3)
FISH analysis 303 (67.5)
Normal 135 (44.6)
13q14.3 83 (27.4)
Trisomy 12 32 (10.6)
11q22.3 29 (9.6)
17p13.1 24 (7.9)
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antibodies specific for human  and  FLCs (kindly provided by Dr A.
Solomon, Knoxville, TN), whose binding was revealed by LSAB
System-HRP (Dako North America) and 3-3-diaminobenzidine (Novocas-
tra) substrate-chromogen. Stained slides were counterstained with hematoxy-
lin and captured by a Leica DM2000 optical microscope (Leica Microsys-
tems). Microphotographs were acquired using a Leica DFC320 digital
camera and imported using Leica IM50 Version 4.0 imaging software
(Leica Microsystems) fitted with a Leica 40/0.65 HI PLAN lens and IM50
acquisition software (Version 4.0).
Statistical analysis
The statistical package SPSS for Windows release 13.0 2004 software
(SPSS) was used for all analyses. For categorical variables, statistical
comparisons were performed using 2-way tables for the Fisher exact test
and multiway tables for the Pearson 2 test. Receiver operating characteris-
tic curve analysis was used to determine the best sFLC(  ) cut-off value
that could discriminate patients who were actually treated from those who
never received therapy at the longest follow-up. TFS analyses were
performed using the Kaplan-Meier method. Statistical significance of
associations between individual variables and survival was calculated using
the log-rank test. The prognostic impact for the outcome variable was
investigated by univariate and multiple Cox regression analysis. Data are
expressed as hazard ratio (HR) and 95% confidence interval (CI). Cox-
derived estimated survival curves according to the combination of prognos-
tic factors were also constructed by the standard approach.20 Because HR
calculates the magnitude of risk rather than the model’s capacity to
accurately classify patient outcome, Harrell C-statistics were used to further
evaluate the discriminatory power of variables in terms of TFS.21 A value of
P 	 .05 was considered significant for all statistical calculations.
Results
Assessment of biologic associations and predictive value of
sFLC(/)
After correction for renal impairment, an abnormal sFLC(/) was
found in 150 of 449 cases (33.4%) and displayed a statistically
significant correlation with expression of CD38 and ZAP-70,
presence of unmutated IGHV, and advanced stage (Table 2); of
note, sFLC(/) failed to correlate with cytogenetic abnormalities.
At a median follow-up of 3 years, 149 of 449 patients had received
treatment. To verify for the potential prognostic relevance of
sFLC(/), patients were divided into 3 groups based on their
normal or abnormal / ratio (clonal  or clonal  cases). The
3-year probability of remaining treatment-free for patients with
abnormal  or  sFLC(/) was significantly lower than those with
a normal sFLC(/) (63.8% vs 70.1% vs 84%, 2 of log-rank 34,
P 	 .0001; Figure 1). As shown by univariate Cox analysis,
advanced stage (Binet B and C) patients (118 of 449; HR 
 2.5,
95% CI, 1.8-3.5, P 	 .0001), those expressing CD38 (80 of 410;
HR 
 2.7, 95% CI, 1.9-3.9, P 	 .0001) or ZAP-70 (140 of 401;
HR 
 4.4, 95% CI, 3.1-6.3, P 	 .0001), those with unmutated
IGHV (130 of 379; HR 
 4.1, 95% CI, 2.8-6.0, P 	 .0001), and
patients with abnormal sFLC(/) (HR 
 2.5, 95% CI, 1.8-3.4,
P 	 .0001) had a statistically significant higher risk of starting
treatment (supplemental Figure 1A, available on the Blood Web
site; see the Supplemental Materials link at the top of the online
Table 2. sFLC ratio abnormality in relation with different biologic and clinical markers in CLL patients
sFLC
All patients, no. (%) Normal, no. (%) Abnormal, no. (%) P
CD38 410 (100) 270 (65.9) 140 (34.1)
Negative 330 (80.5) 234 (70.9) 96 (29.1) 	 .0001*
Positive 80 (19.5) 36 (45.0) 44 (55.0)
ZAP-70 401 (100) 267 (66.6) 134 (33.4)
Negative 261 (65.1) 191 (73.2) 70 (26.8) 	 .0001†
Positive 140 (34.9) 76 (54.3) 64 (45.7)
IGHV status 379 (100) 257 (67.8) 122 (32.2)
Mutated 249 (65.7) 182 (73.1) 67 (26.9) .003*
Unmutated 130 (34.3) 75 (57.7) 55 (42.3)
Binet stage 449 (100) 299 (66.6) 150 (33.4)
A 331 (80.5) 232 (70.1) 99 (29.9) .012*
B  C 118 (19.5) 67 (56.8) 51 (43.2)
FISH 303 (100) 205 (67.7) 98 (32.3)
13q14.3 and normal (low risk) 208 (71.9) 154 (70.6) 64 (29.4)
Trisomy 12 (intermediate risk) 32 (10.6) 19 (59.4) 13 (40.6) .20†
11q22.3 and 17p13.1 (high risk) 53 (17.5) 32 (60.4) 21 (39.6)
*Fisher Exact Test.
†Pearson 2 text.
Figure 1. TFS of 449 patients with CLL according to the sFLC assay. Kaplan-
Meier curves show the 3-year probability of remaining treatment-free for CLL cases
subdivided into 3 groups based on their normal [normal sFLC(/)] or abnormal  or 
sFLC ratio. The 3-year TFS was significantly lower in patients with  or  sFLC(/).
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article). Notably, abnormal sFLC(/) (HR 
 2.2, 95% CI, 1.5-3.2,
P 	 .0001) retained an independent association with TFS even
when adjusted for CD38, ZAP-70 expression, IGHV mutational
status, and Binet stage. ZAP-70 (HR 
 3.0, 95% CI, 1.9-4.8,
P 	 .0001), unmutated IGHV (HR 
 1.9, 95% CI, 1.1-3.2,
P 
 .014), and Binet stage (HR 
 2.4, 95% CI, 1.6-3.7, P 	 .0001)
remained independently associated with the risk of requiring
therapy, whereas CD38 expression was no longer predictive
(supplemental Figure 1B).
Assessment of the predictive value of sFLC(  )
To further dissect the potential predictive value of sFLC, the - and
-FLC concentrations were summed to produce a new variable,
named sFLC(  ) (median, 39.0 mg/mL; range, 8.2-1430.4 mg/
mL, supplemental Figure 2A). Because a significantly higher
sFLC(  ) was observed in CLL patients who had required
treatment (supplemental Figure 2B), a cut-off value was estab-
lished to resolve the power of sFLC(  ) of identifying patients
who were actually treated from those who remained treatment-free
at the longest follow-up. Receiver operating characteristic analysis
disclosed that 60.6 mg/mL was the most suitable sFLC(  )
cut-off value (area under the curve 
 .62, P 	 .0001). At 3 years,
the probability of being therapy-free was 84.1% and 51.8% for
patients with a sFLC(  ) value below and equal (n 
 365) or
above (n 
 84) the cut-off value, respectively (2 of log-rank 85.6,
P 	 .0001, Figure 2A). Interestingly, Cox multivariate analysis
suggested that the independent predictive value of sFLC(  )
above the cut-off (HR 
 2.5, CI, 2.6-3.9) remained one of the
strongest predictive parameters together with ZAP-70 (HR 
 2.8,
CI, 1.8-4.6) and Binet stage (HR
 2.5, CI, 1.6-3.8), whereas CD38 as
well as IGHV mutational status lost their prognostic power.
Relationship between sFLC(  ) and sFLC(/)
Because each of the 2 patient cohorts defined by the presence of a
summated FLC value below or above the cut-off (Figure 2A)
derived from the concurrence of cases with an excess monoclonal
sFLC production (ie, with an abnormal sFLC ratio) and cases with
an excess polyclonal sFLC production (ie, with a conserved sFLC
ratio), we considered it appropriate to further dissect these cohorts.
To this end, we proceeded to analyze separately the outcome of
patients with both normal sFLC(/) and sFLC(  ) below the
cut-off (277 of 449, 61.7%) or both abnormal sFLC(/) and
sFLC(  ) above the cut-off (62 of 449, 13.8%), defined as
“concordant cases” (75.5%), and the outcome of patients with
either normal sFLC(/) and sFLC(  ) above the cut-off (22 of
110, 20%) or abnormal sFLC(/) and sFLC(  ) below the
cut-off (88 of 110, 80%), defined as “discordant cases” (110 of 440,
24.5%; Figure 2B). The estimated Kaplan-Meier curves for TFS
according to the combination of sFLC(/) abnormality and
sFLC(  ) cut-off values are shown in Figure 2C. To better
illustrate the predictive impact of summated sFLC on TFS, separate
curves for patients with normal (Figure 2D) or abnormal sFLC ratio
(Figure 2E) are shown with respect to the sFLC(  ) cut-off.
Notably, a Cox multivariate model showed that sFLC(  )
above cut-off yields an approximately 3-fold higher risk of early
treatment requirement than abnormal sFLC(/): HR 
 3.5, CI,
2.4-5.1 (P 	 .0001) versus HR 
 1.5, CI, 1.1-2.3 (P 
 .015).
To investigate which FLC-related parameter could provide a
more accurate prediction of TFS, a c-statistic analysis, considered a
measure of concordance between observed and predicted time-
dependent events, was carried out. The results demonstrated that
both the sFLC(/) (c 
 .51, P 	 .001) and the sFLC(  )
(c 
 .52, P 	 .001) were able to correctly predict TFS.
Distribution of cytogenetic abnormalities among sFLC(  )
and sFLC(/)
A total of 303 samples were investigated by interphase FISH for the
presence of the major genomic aberrations. The overall incidence
was as follows: (1) 13q14.3 deletion, 83 of 303 (27.4%) and normal
in 135 of 303 (overall 218, 44.6%, low risk group); (2) trisomy 12, 32 of
303 (10.6%, intermediate risk group); and (3) 11q22.3 deletion, 29 of
303 (9.6%) and 17p13.1 deletion 24 of 303 (7.9%, high risk group).
Interestingly, a statistically significant association was documented for
risk as defined by FISH analysis and sFLC( ) (P
 .013, Figure
3A), but not with sFLC(/) values.
Supplemental Figure 3 shows the Kaplan-Meier curves of cases
stratified by cytogenetic risk. The estimated median times to
treatment need were 12.1, 6.5, and 3.1 years for cases with low,
intermediate, and high risk, respectively. Notably, abnormal
sFLC(/) (HR 
 2.0, 95% CI, 1.3-3.1) and sFLC(  ) above
the cut-off (HR 
 2.8, 95% CI, 1.7-4.5) retained an independent
association with TFS together with cytogenetics, ZAP-70 expres-
sion, and Binet stage (Figure 3B-C). Finally, results from a
multivariate model in which both sFLC(  ) and sFLC(/)
parameters were considered together showed that the latter failed to
retain an independent association with TFS, whereas sFLC(  )
(HR 
 2.3, 95% CI, 1.3-4.1, P 
 .004) still remained a significant
prognostic factor together with cytogenetics (HR 
 2.1, 95% CI,
1.5-2.7, P 	 .0001), ZAP-70 (HR 
 2.8, 95% CI, 1.7-4.8,
P 	 .0001) expression, and Binet stage (HR 
 2.8, 95% CI,
1.7-4.6, P 	 .0001).
A novel prognostic scoring system based on the integration
sFLC(  ) with 3 biomarkers
Based on the results of multivariate and c-statistic analyses, we
wished to test the hypothesis that the combination of sFLC(  ),
ZAP-70 expression, and FISH abnormalities together with Binet
stage could allow a more finely tuned estimation of prognosis. To
this end, we divided cases of our study cohort into 5 groups
according to the negative prognostic impact of these biomarkers. A
scoring system was then designed in which 1 point was assigned to
each unfavorable prognostic marker and the final score was given
by the sum of the unfavorable markers present. Based on this
analysis of 262 patients, 104 cases scored 0 (low risk), 79 scored
1 (low-intermediate risk), 56 scored 2 (intermediate-high risk),
19 scored 3, and only 4 cases scored 4. Considering the relatively
low number of cases in the latter 2 score groups, we combined them
to form the high-risk group (23 patients). According to this
classification, the 3-year probability of avoiding treatment was 94.8%,
84.5%, 61.6%, and 21.1%, respectively, for patients in the low,
low-intermediate, intermediate-high, and high risk groups (Figure 4).
In situ immunohistochemical detection of  and  FLCs in the
CLL microenvironment
After analysis of the prognostic significance of sFLC(  ), we
investigated the actual presence and distribution of FLCs in CLL
infiltrates in situ, by immunohistochemistry using 2 validated
monoclonal antibodies specifically recognizing the unbound light
chains.21 Consistent with the hypothesized concurrence of different
B-cell populations of FLC synthesis in the CLL microenvironment,
we detected, along with a prevalent population of plasmacytoid
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lymphocytes showing cytoplasmatic reactivity of either of the
2 FLCs, in accordance with the predominant clonal chain (Figure
5A,D), a lower amount of lymphoid elements also showed partial
reactivity of the nonclonal FLC (Figure 5B-C). These lymphocytes
expressing different FLC types populated the same infiltrates in the
lymph node and bone marrow and were associated with scattered
FLC-producing plasma cells (Figure 5A-D insets). The specificity
of the immunohistochemistry detection of FLCs was confirmed by
the analysis of  and  expression in MM bone marrow infiltrates,
in which FLC expression was almost entirely confined to the
clone-related light chain (supplemental Figure 4). This preliminary
demonstration of clone-related and unrelated light chain in the CLL
microenvironment strengthens the rationale for assessment of
sFLC(  ).
Discussion
The management of CLL needs to be tailored to the expected
disease course and to the patient’s ability to tolerate treatments. An
Figure 2. Predictive value of a novel parameter sFLC(  ) and relationship with sFLC(/) ratio. (A) Kaplan-Meier curves demonstrating a significantly shorter 3-year
TFS for those CLL cases with sFLC(  ) reaching or exceeding the cut-off value (51.8%, 2 of log-rank 85.6, P 	 .0001). (B) Comparison of CLL cases in terms of sFLC(/)
and sFLC(  ) variables with respect to sFLC(  ) cut-off value of 60.6 mg/mL. Of a total of 449 cases, 277 (61.7%) had normal sFLC(/) and sFLC(  ) below the
cut-off, 62 (13.8%) had both abnormal sFLC(/) and sFLC(  ) above the cut-off with a concordance rate of 75.5%, 110 cases were discordant (24.5%) with 22 normal
sFLC(/) and sFLC(  ) above the cut-off, and 88 with abnormal sFLC(/) and sFLC(  ) below the cut-off. (C) Estimated Kaplan-Meier curves of TFS according to the
combination of sFLC(/) abnormality and sFLC(  ) cut-off value. To better illustrate the predictive impact of summated sFLC on TFS, separate curves for patients with
normal (D) or abnormal sFLC ratio (E) are shown with respect to the sFLC(  ) cut-off.
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ideal prognostic biomarker, beyond being technically simple and
cost-effective, should stratify untreated patients according to risk of
progressive disease and shorter survival. This would allow identifi-
cation of patients who may potentially benefit from early therapy
and spare others unnecessary treatment-related toxicity.
Given its ability to accurately identify and monitor clonal B-cell
populations, the sFLC assay has been explored as a potential new
prognostic tool for CLL.7,8 Independent investigations have shown
that 40% to 53% of CLL patients display an abnormal sFLC(/)
and/or elevated levels of clonally unrestricted  or  sFLC, which
have been proposed to identify cases with poor survival and early
treatment requirement.7,8 Results of these retrospective studies are
varied in terms of the prognostic value and independent impact of
sFLC-dependent variables within the context of common CLL
biomarkers. Pratt et al showed that sFLC(/) abnormalities
predicted TFS if both treated and therapy-naive patients were
grouped together; however, statistical significance did not hold if
untreated patients were analyzed separately.7 Yegin et al reported
that, although sFLC elevations identify patients requiring early
treatment, median TFS did not statistically differ between cases
with or without abnormal sFLC(/).8 Similarly, sFLC(/) abnor-
malities correlated with ZAP-70 but not with CD38 expression in
the former study,7 whereas the opposite result was found in the
latter.8 More importantly, sFLC levels and sFLC(/) abnormali-
ties failed to stratify patients according to cytogenetic risk in one
study, whereas FISH data were not reported in the other.7,8
By analyzing the largest reported cohort (n 
 449) of untreated
CLL patients, concurrently characterized for established CLL
biomarkers, we document herein that sFLC(/) and sFLC levels
are distinct prognostic variables in CLL. Although abnormal
sFLC(/) was associated with parameters reflecting disease
aggressiveness (ie, stage, CD38/ZAP-70, IGHV mutations, and
independently predicted TFS), it did not correlate with cytogenetic
risk. In contrast, unfavorable cytogenetics were associated with a
novel biologic variable, namely, the sFLC(  ), representing the
sum of absolute  and  sFLC protein levels, irrespective of
sFLC(/) abnormalities. Accordingly, we documented that the
prognostic impact of an abnormal sFLC(/) becomes irrelevant if
the sFLC(  ) value is above a threshold (ie, 60.6 mg/mL)
derived from receiver operating characteristic analysis to discrimi-
nate patients who were actually treated from those never given
therapy at the longest follow-up. Indeed, on multivariate analysis,
sFLC(  ) more than 60.6 mg/mL remained the strongest predic-
tor of TFS together with ZAP-70, staging, and cytogenetics,
whereas CD38, IGHV mutations, and sFLC(/) abnormalities lost
Figure 4. TFS of CLL patients according to a prognostic scoring system,
including the sFLC(  ) parameter. Kaplan-Meier curves show the probability of
remaining treatment-free for CLL cases subdivided according to a scoring system
designed to evaluate unfavorable negative prognostic biomarkers: 1 point was
assigned to each unfavorable prognostic marker [ZAP-70 expression, FISH abnormali-
ties, Binet stage, and sFLC(  )], and the final score was given by the sum of the
unfavorable markers present. A total of 262 patients were analyzed producing the
following scores: 104 cases scored 0 (low risk), 79 scored 1 (low-intermediate risk),
56 scored 2 (intermediate-high risk), and 23 cases scored 3 or 4 (high risk) with a
3-year TFS of 94.8%, 84.5%, 61.6%, and 21.1%, respectively.
Figure 3. Comparison of cytogenetic risk and total sFLC. (A) CLL patients
(n 
 303), stratified by cytogenetic risk (low risk, normal and 13q14.3; intermediate
risk, trisomy 12; high risk, 11q22.3 and 17p13.1) groups showed a significant
correlation with sFLC(  ) cut-off value (60.6 mg/mL). Forest plots indicating
(B) an abnormal sFLC(/) (HR 
 2.0, 95% CI, 1.3-3.1) and (C) sFLC(  ) above
the cut-off (HR 
 2.8, 95% CI, 1.7-4.5) retained an independent association with TFS
together with cytogenetics, ZAP-70 expression, and Binet stage in Cox multivariate
models.
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their prognostic power. A straightforward model, including
sFLC(  ) more than 60.6 mg/mL, Binet staging, ZAP-70, and
cytogenetics, was validated to accurately predict time to treatment
requirement in untreated CLL patients.
A high summated level of  plus  FLC could derive from the
concurrence of cases with an excess monoclonal production (ie,
with an abnormal FLC ratio) and cases with an excess polyclonal
production (ie, with a normal FLC ratio), within the context of
normal/defective kidney function. Even though CLL is not typi-
cally associated with renal injury, we excluded biases from
non–tumor-related renal impairments by adopting adjusted sFLC
normality ranges, in patients with impaired creatinine clearance.5 A
separate analysis of patients with normal or abnormal FLC ratio
indicated that a sFLC(  ) above the cut-off retained its ability
to predict TFS in both groups. A direct comparison evidenced that
patients with a normal FLC(/) and sFLC(  ) above threshold
displayed a poorer TFS outcome compared with all those with an
sFLC(  ) below the cut-off, irrespective of ratio abnormalities.
Interestingly, the outcome of patients concurrently displaying
elevated sFLC(  ) and abnormal sFLC(/) was not statisti-
cally different from those with sFLC(  ) above the cut-off and
a normal ratio. Both these cohorts of patients had the worst TFS.
These data, beyond confirming our multivariate model, suggest that
sFLC(/) and sFLC(  ) reflect different phenomena in the
complex biology of CLL.
Until recently, attention has been mostly focused on sFLC(/)
and levels of “involved” (clonal) FLCs, which, being secreted by
tumor cells, were thought to reflect size and biologic activity of the
malignant B-cell population.2 Modern views maintain that CLL
arises from activated, antigen-experienced B cells, suggesting that
persistent immune stimulation and ongoing polyclonal B-cell
activation/dysfunction may play an important role in the develop-
ment and progression of this malignancy.22 Polyclonal B cells share
the same microenvironmental interactions as tumor cells and could
themselves be activated on antigenic stimulation of the CLL
clone.23 This latter may in turn convey activatory signals to
bystander B and T lymphocytes.24,25 In this scenario, tumor-derived
monoclonal FLCs can be admixed with variable amounts of sFLC
produced by nonclonal bystander B cells in lymphohematopoietic
tissues. We documented a concurrence of these different B-cell
populations to FLC synthesis within the CLL microenvironment.
Our immunohistochemistry studies showed that tumor cells produc-
ing clonally restricted FLCs coexist with variable amounts of
lymphocytes expressing nonclonal FLCs in infiltrated bone marrow
and lymph nodes. These latter B cells might be in part clonally
related to the dominant CLL clone and/or mirror an expanding
antigen-stimulated polyconal B-cell pool.24 Interestingly, an ongo-
ing B-cell activation/expansion, reflected by the overproduction of
polyclonal sFLC, underlies the pathogenesis of several inflamma-
tory/autoimmune conditions, which are themselves associated with
an increased risk of non-Hodgkin lymphoma.26 Along this line, Tsai
et al demonstrated that 38% of patients eventually developing CLL
displayed an abnormal sFLC(/) up to 10 years before diagnosis
and another 16% of them had a sustained polyclonal sFLC
elevation in the same prediagnostic time frame.27 As such, eleva-
tions in both the “involved” sFLC (ie, the same clonally restricted
light chain later found on tumor cells) and “uninvolved” FLCs can
be found during pre-CLL phases.27 Similarly, it was shown that
“low-count” monoclonal B-cell lymphocytosis, which shares many
phenotypic traits of CLL, may actually be oligoclonal by reflecting
the expansion of diversified, clonally related, populations with
evidence of antigen drive.28 Finally, the presence of polyclonal
sFLC elevations was shown to represent a strong risk factor for
non-Hodgkin lymphoma development in HIV-infected persons.29
Although the mechanisms underlying polyclonal/oligoclonal FLC
synthesis in “premalignant” CLL phases may reflect recruitment of
multiple B-cell populations because of chronic antigenic challenge,
the emergence of nonclonal FLCs at an overt tumor stage, as
suggested by our study, is more puzzling. The coexistence of clone
“side populations,” with a diversified light-chain repertoire result-
ing from aberrant recombinase activity, could be hypothesized
given that Ig recombination also occurs in mature B-cell popula-
tions, on persistent autoantigenic stimulation, to preserve/restore
tolerance.30-33 Thus, molecular events involving the neoplastic
clone and the environmental stimuli sustaining bystander B-cell
Figure 5. In situ immunohistochemical detection of
free  and  chains in the CLL microenvironment.
(A-B) In lymph node infiltrates of a -chain CLL case, a
prominent population of plasmacytoid lymphocytes ex-
pressing the  FLC is detected along with a lower number
of lymphocytes showing expression of the clone-unre-
lated  chain, both populating the same microenviron-
ment. Scattered plasma cells with either  or  FLC
expression are also detected (panels A and B insets).
(C-D) A similar picture is observed in bone marrow
lymphoid infiltrates of a -chain CLL case. Immunohisto-
chemistry performed by the streptavidin–avidin-biotin
complex using the 3-3-diaminobenzidine chromogen
(brown signal). Original magnifications 200 for all pan-
els and400 for insets.
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activation may both concur to the sFLC pattern of CLL and to its
prognostic relevance.
The overproduction of nonclonal sFLC in CLL patients may
not necessarily be related to tumor biology. Results of population-
based studies have indicated that overproduction of nonclonal
sFLC could predict mortality in individuals older than 50 years,
who were either healthy or affected by various comorbidities.34
Based on these findings, polyclonal sFLC elevation was inter-
preted as a nonspecific marker of “unwellness,” which reflects a
generalized immune overstimulation occurring in elderly
subjects.34
Contextualizing this view to our cohort of aged CLL patients
would, however, argue in favor of the highly significant association
of the sFLC(  ) variable with intrinsic features of tumor cells,
such as ZAP-70 and unfavorable cytogenetics, and its strong and
independent predictive power on TFS. Although host “fitness” may
certainly affect overall survival of CLL patients, its direct influence
on time to treatment requirement, an outcome mostly related to
tumor biologic aggressiveness itself, is more complex to
demonstrate.
Independently of the mechanisms underlying the overproduc-
tion of sFLCs, these can “per se” endorse immunobiologic
activities relevant to CLL pathobiology. For instance, despite
being usually regarded as a mere spillover product of Ig
synthesis/assembly, FLCs could activate mast cells, which
enrich the CLL microenvironment.35 Activated mast cells may in
turn support tumor cell growth and foster immune stimulation
through different pathways, including CD40- and IL-6–
mediated signaling.36
In conclusion, our findings support that the cumulative amount
of circulating FLC, irrespective of their clonality, is a strong and
independent prognostic predictor in CLL. A new scoring system,
involving the simple, reproducible, and cost-effective sFLC assay,
is proposed to identify at diagnosis CLL patients who are more
likely to require early treatment.
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